A new cost-benefit analysis conducted by the Johns Hopkins Bloomberg School of Public Health and others suggests that $6 million in costs related to the opioid epidemic could be saved each year if a single “safe consumption” space for illicit drug users were opened in Baltimore.
It would also reduce overdose deaths, HIV and hepatitis C infections, overdose-related ambulance calls and hospitalizations – and bring scores of people into treatment, they found.
Carefully monitored “safe consumption” spaces, which are not legal in the United States but have been used in dozens of cities around the world, provide a clean indoor environment in which people can use their own drugs with medical personnel on hand to reverse overdoses should they occur. These facilities serve as access points to substance use disorder treatment and other vital social services for drug users, such as medical care and housing.
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA granted the application priority review and previously granted Opdivo orphan-drug designation for the treatment of HCC. The FDA action date is September 24, 2017.
“We believe the FDA acceptance of our application for Opdivo with priority review status is an important recognition of the significant unmet need for patients with HCC, which is often diagnosed in the advanced stage when treatment options are limited,” said Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb. “We are committed to exploring new treatment options for these patients and look forward to working with the FDA to potentially extend the use of Opdivo as a treatment option in this setting.”
The submission was based on data from the Phase 1/2 CheckMate -040 study investigating Opdivo in advanced HCC patients with and without hepatitis B virus or hepatitis C virus infections. Data from this study were recently published in The Lancet and will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 during a poster discussion session on June 3, 2017 from 4:45–6:00 PM CDT in Hall D2.
Despite reports of expanding rates of injecting drug use in a new list of countries around the world, no new countries have established needle and syringe programmes in the last three years.
This is one of the headline findings of an exhaustive review of the state of harm reduction services around the world conducted by international NGO Harm Reduction International, presented at the 25th International Harm Reduction Conference (HR17) in Montréal last week.
The absence of any increase in the number of countries that report starting needle and syringe programming is significant. Katie Stone, Research Analyst with Harm Reduction International describes this problem:
An interview with hepatitis C survivor and Think About the Link® spokesperson Alejandro Escovedo
The Prevent Cancer Foundation® recently announced Mexican-American singer/songwriter Alejandro Escovedo as a national spokesperson for the Think About the Link® campaign. This educational campaign aims to raise awareness of the connection between certain viruses (HPV, hepatitis B, and hepatitis C) and cancer. You can check out our Spanish site here: www.piensaenelvinculo.org.
As a hepatitis C survivor, Escovedo is no stranger to the detrimental effects of the virus that is growing more common among the Hispanic population. An estimated 40,710 Americans will be diagnosed with liver cancer this year, and hepatitis C will cause at least 50 percent of these cases. Most people who are infected with hepatitis C don’t know it—that’s why Think About the Link® encourages all adults (especially baby-boomers) to get screened for hepatitis C, and if positive, talk to your health care provider about getting available treatment options.
Note: Hepatitis D (HDV) is one of the most severe forms of hepatitis. In order for it to replicate it requires the hepatitis B virus–both hepatitis viruses are serious and potentially life-threatening diseases. Currently, there are no approved medications to treat hepatitis D. Pegylated interferon has been used with some success–less than one-quarter of people who are treated have successfully resolved or cleared the hepatitis D virus. Some studies have combined hepatitis B antiviral medications with pegylated interferon, but again the success rates have been very low. This is why new medications are needed. While the press release below highlights a drug in early development it does offer much-needed hope for a new medication to treat this disease. If you have not been infected with hepatitis B, get vaccinated. It will protect against hepatitis D! Alan for www.hcvadvocate
MOSCOW, May 25, 2017 /PRNewswire/ —
MYR GmbH and its development partner Hepatera LLC today announced that the European Medicines Agency (EMA) granted “PRIME eligibility” for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus.
“It is very encouraging that the European regulator recognizes the importance of the unmet medical problem in hepatitis delta and is willing to support the development of Myrcludex B,” said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR’s Clinical Advisory Board. “The affected patients are in urgent need of new medications and we are looking forward to the upcoming results of the Phase 2b program with this innovative drug.”
“The combined efforts of academic research, public funding and small biotech development and venture activities allowed the clinical development of a completely new drug with a novel mode of action on both Hepatitis B and D virus. The enhanced dialog with EMA will now strongly facilitate further joint effort to bring Myrcludex B to the HDV/HBV co-infected patients in need as fast as possible,” commented Stephan Urban, PhD, DZIF-Professor for Translational Virology at the University of Heidelberg, inventor of the technology and collaboration partner of MYR GmbH and Hepatera LLC.
Note: This is a very interesting program. The goal is to eliminate hepatitis C in the European country of Georgia. Georgia has one of the highest rates of hepatitis C in the world. It will provide a wealth of information. Alan for www.hcvadvocate.org
Those living in Georgia’s occupied regions but do not hold a Georgian passport will be able to benefit from the free Hepatitis C treatment program Georgia offers its citizens.
Georgian Health Minister David Sergeenko announced this after a governmental meeting today.
Sergeenko said that a neutral ID card or a neutral travel document will be enough for Abkhazia and Tskhinvali region residents to engage in the free treatment program.
President Donald Trump’s 2018 budget proposal released this week includes major cuts to medical research and health services for low-income people that would have a devastating impact on people living with HIV, advocates said.
Medicaid, disability insurance, food stamps, and children’s health coverage are all on the chopping block, while the $4.1 trillion budget would beef up spending for the military and immigration and border control.
“The Trump administration’s FY 2018 budget is the first one since the president took office and as such it reflects his priorities for our nation,” Ernest Hopkins, director of legislative affairs at the San Francisco AIDS Foundation, told the Bay Area Reporter. “It is a messaging document, and the message is that President Trump is willing to gut essential health and social service programs for our most vulnerable citizens in exchange for missiles and bombs.”
Mistakenly considered a baby-boomer disease, hepatitis C is growing rapidly among young drug addicts — who often don’t know they’re infected
A growing number of young, suburban New Jerseyans with opiate addictions are also infected with hepatitis C, according to a new study. These findings reflect a national trend that has prompted healthcare providers to seek more effective ways to connect patients with treatment and reduce the spread of the disease.
A hep-C screening program at Princeton House Behavioral Health, a healthcare network in central New Jersey, found more than 41 percent of the heroin addicts they tested in recent years were positive for the blood-borne virus, which can lie dormant for years but eventually destroy the liver and even cause death.